Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

5-methyl-pyridine-2-sulfonic acid {6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt

EU orphan designation number: EU/3/03/182   
Active ingredient: 5-methyl-pyridine-2-sulfonic acid {6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt
Indication: Treatment of aneurysmal subarachnoid haemorrhage
Sponsor: Actelion Registration Ltd
Cheswick Tower, 13th floor, 389 Cheswick High Road, London W4 4AL, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
16/12/2003 Centralised Orphan - Designation EMEA/OD/057/03 (2003)5039 of 12/12/2003
10/01/2005 Centralised Orphan - Transfer of orphan designation EMEA/OD/057/03/T/01 (2004)5731 of 06/01/2005
02/07/2014 Centralised Orphan - Change of address